Dr. Stefano Picozzi, (Milan, Italy) was defending emergency SWL treatmant, and Dr. Juan Galan Llopes from Alicante, Spain was defending emergency URS, and finally Dr. Thomas Lam from Aberdeen, UK was defending the use of alpha-blockers and Dr. Andreas Gross from Hamburg, Germany was defending emergency stenting. The debate was on the effectiveness of all these treatment modalities in the setting of emergency obstructive ureteral stone.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The next debated in this session was Dr. Galan who started his lecture with the statement that most patients are concerned about their pain at the time of renal colic in the emergency department and urologist’s primary concern must be relieving patients pain and deal with the stone at a later stage. Apparently, 87% of patients would agree with a 4 week trial of MET. When patients are asked about the preference of active treatment, the majority would prefer ESWL, which is considered the least invasive procedure, however patients preference shifts to URS after physicians provide more information on the success rates of both, URS and ESWL procedures. The current state of literature and data on the emergency use URS is poor with only one prospective trial and 1 meta-analysis. Although no big difference in stone free rate, patients can be rendered pain free faster with an emergency procedure. Dr. Galan concluded that although URS is effective, 90% of patients will need a stent post-operatively and subsequent follow up visit to remove the ureteral stent.
The third presenter on this debate session was Dr. Lam who advocated for MET treatment based on the SUSPEND prospective randomized trial published by McClinton and colleauges in 20146. He continued that all meta-analyses on the subject show a benefit of MET over placebo. They also all, expect for the one from Hollingsworth published in 20167, acknowledge that there is a large methodological and statistical heterogeneity, small studies included and publication bias8. Dr. Lam further defined that the current data would indicate that MET is most useful for distal stones >5mm and <10mm. He emphasized that meta-analysis, including only high-quality studies would be useful as well as a nomogram to identify the probable responders to MET.
Final debater of the session, Dr. Gross started off with the a statement that he has a very busy ED department of 50,000 visits per year, in which renal colic is the 9th most common cause of visit. He expressed that as most patients with a renal colic are in pain at the time of ED visit, there is no time for a lengthy discussion with the patient about stone free rates, complication rates, etc. He continued that all URS, SWL and MET are all excellent treatment options; however, he reinforced that ESWL has a high chance of needing retreatment and the limitation of URS is that patients need to be stented and subsequent visits are required to remove the stent. Dr. Gross said he believes that MET does not help in the first 2 weeks of the treatment (no reference provided).
Emergency stenting has multiple benefits. The patient is relieved of pain immediately, gaining access with ureteroscope is more successful in pre-stented patients and pre-stented patients have a lower chance of needing a stent after the URS. He also feels that pre-stented patients have less bleeding during URS. In the discussion, Dr. Picozzi holds true to his principle and would SWL any stone in the ureter of <10mm if there is no indication of infection or contra-indication for SWL. Interestingly, many of the patients in Dr. Galan’s service may have had a trial of MET prior to their first visit to the urologist. Dr. Lam emphasizes that it remains difficult to identify the ideal patient and ideal treatment window for a trial of MET.
Presenter: Beat Roth, MD; Department of Urology, University of Bern, Bern, Switzerland
Written By: Zhamshid Okhunov, MD, University of California, Irvine
at the #EAU17 - March 24-28, 2017- London, England